Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 5/2016

15.02.2016 | Oculoplastics and Orbit

Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy

verfasst von: Ji Won Kim, Sun Hyup Han, Byeong Jae Son, Tyler Hyungtaek Rim, Ki Chang Keum, Jin Sook Yoon

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the efficacy and safety of combination therapy with orbital irradiation and systemic steroids versus steroid monotherapy in the management of active Graves’ orbitopathy (GO).

Methods

The clinical charts of 127 patients with active inflammation due to GO who received intravenous steroid pulse therapy as a first-line treatment with or without orbital radiotherapy between 2010 and 2014 were reviewed. Patients were divided into two treatment groups: 1) combined orbital radiotherapy and steroid pulse therapy (SRT group) and 2) steroid pulse therapy only (ST group). Primary outcome measures included clinical activity score (CAS); NOSPECS classification; ocular motility impairment; and exophthalmos at 1, 3, 6, and 12 months after treatment. The secondary outcome measure was the change in orbital, extraocular muscle (EOM), and fat volume after treatment measured by orbit computed tomography.

Results

Sixty-eight patients were included in the SRT group, and 59 patients were in the ST group. In both treatments, CAS and NOSPECS were significantly reduced. In the comparison of the degree of change from baseline between the groups, the SRT group demonstrated more improvement in NOSPECS and scores of ocular motility. Orbital, EOM, and fat volume significantly decreased in the SRT group; however, only fat volume was reduced in the ST group. Compressive optic neuropathy after treatment developed in 0 % of the SRT group and 3.4 % (2/59) of the ST group. Reactivation of inflammation occurred in 11.8 % (8/68) of the SRT group and 28.8 % (17/59) of the ST group.

Conclusions

Orbital radiotherapy in combination with steroid treatment significantly improved ocular motility by reducing EOM volume in patients with active GO.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285. doi:10.1530/eje-07-0666 CrossRefPubMed Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158(3):273–285. doi:10.​1530/​eje-07-0666 CrossRefPubMed
3.
Zurück zum Zitat Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86(8):3562–3567. doi:10.1210/jcem.86.8.7737 PubMed Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves’ ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86(8):3562–3567. doi:10.​1210/​jcem.​86.​8.​7737 PubMed
4.
Zurück zum Zitat Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90(9):5234–5240. doi:10.1210/jc.2005-0148 CrossRefPubMed Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90(9):5234–5240. doi:10.​1210/​jc.​2005-0148 CrossRefPubMed
6.
Zurück zum Zitat Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G (2001) High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest 24(3):152–158CrossRefPubMed Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G (2001) High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest 24(3):152–158CrossRefPubMed
7.
8.
Zurück zum Zitat Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, Ohtakara S, Morimoto I, Okamoto S, Nagataki S (1987) Treatment of Graves’ ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 116(4):513–518 Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, Ohtakara S, Morimoto I, Okamoto S, Nagataki S (1987) Treatment of Graves’ ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol (Copenh) 116(4):513–518
9.
Zurück zum Zitat Guy JR, Fagien S, Donovan JP, Rubin ML (1989) Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 96(7):1048–1052, discussion 1052–1043 CrossRefPubMed Guy JR, Fagien S, Donovan JP, Rubin ML (1989) Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 96(7):1048–1052, discussion 1052–1043 CrossRefPubMed
10.
Zurück zum Zitat Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, Nishimura H, Nishida H, Kaise N (1993) Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J 40(1):63–72CrossRefPubMed Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, Nishimura H, Nishida H, Kaise N (1993) Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J 40(1):63–72CrossRefPubMed
13.
Zurück zum Zitat Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 108(9):1523–1534CrossRefPubMed Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB (2001) A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology 108(9):1523–1534CrossRefPubMed
15.
Zurück zum Zitat Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9–14CrossRef Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9–14CrossRef
16.
Zurück zum Zitat Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91(9):3464–3470. doi:10.1210/jc.2005-2813 CrossRefPubMed Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91(9):3464–3470. doi:10.​1210/​jc.​2005-2813 CrossRefPubMed
17.
Zurück zum Zitat Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, Mourits MP (2008) A new and validated CT-based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci 49(5):1758–1762. doi:10.1167/iovs.07-1030 CrossRefPubMed Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, Mourits MP (2008) A new and validated CT-based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci 49(5):1758–1762. doi:10.​1167/​iovs.​07-1030 CrossRefPubMed
19.
Zurück zum Zitat Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342(8877):949–954CrossRefPubMed Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342(8877):949–954CrossRefPubMed
21.
Zurück zum Zitat Ng CM, Yuen HK, Choi KL, Chan MK, Yuen KT, Ng YW, Tiu SC (2005) Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med J 11(5):322–330PubMed Ng CM, Yuen HK, Choi KL, Chan MK, Yuen KT, Ng YW, Tiu SC (2005) Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy: a preliminary study. Hong Kong Med J 11(5):322–330PubMed
22.
Zurück zum Zitat Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426. doi:10.1002/art.21984 CrossRefPubMed Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426. doi:10.​1002/​art.​21984 CrossRefPubMed
23.
Zurück zum Zitat Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Buettner H, Robertson DM, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB (2002) The aftermath of orbital radiotherapy for graves’ ophthalmopathy. Ophthalmology 109(11):2100–2107CrossRefPubMed Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Buettner H, Robertson DM, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB (2002) The aftermath of orbital radiotherapy for graves’ ophthalmopathy. Ophthalmology 109(11):2100–2107CrossRefPubMed
24.
Zurück zum Zitat Wu Y, Tong B, Luo Y, Xie G, Xiong W (2015) Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study. Int J Clin Exp Med 8(2):2086–2096PubMedPubMedCentral Wu Y, Tong B, Luo Y, Xie G, Xiong W (2015) Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study. Int J Clin Exp Med 8(2):2086–2096PubMedPubMedCentral
26.
Zurück zum Zitat Hahn E, Laperriere N, Millar BA, Oestreicher J, McGowan H, Krema H, Gill H, DeAngelis D, Hurwitz J, Tucker N, Simpson R, Chung C (2014) Orbital radiation therapy for Graves’ ophthalmopathy: measuring clinical efficacy and impact. Pract Radiat Oncol 4(4):233–239. doi:10.1016/j.prro.2014.02.008 CrossRefPubMed Hahn E, Laperriere N, Millar BA, Oestreicher J, McGowan H, Krema H, Gill H, DeAngelis D, Hurwitz J, Tucker N, Simpson R, Chung C (2014) Orbital radiation therapy for Graves’ ophthalmopathy: measuring clinical efficacy and impact. Pract Radiat Oncol 4(4):233–239. doi:10.​1016/​j.​prro.​2014.​02.​008 CrossRefPubMed
27.
28.
Zurück zum Zitat Bartalena L, Marcocci C, Manetti L, Tanda ML, Dell’Unto E, Rocchi R, Cartei F, Pinchera A (1998) Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 8(5):439–441CrossRefPubMed Bartalena L, Marcocci C, Manetti L, Tanda ML, Dell’Unto E, Rocchi R, Cartei F, Pinchera A (1998) Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 8(5):439–441CrossRefPubMed
Metadaten
Titel
Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy
verfasst von
Ji Won Kim
Sun Hyup Han
Byeong Jae Son
Tyler Hyungtaek Rim
Ki Chang Keum
Jin Sook Yoon
Publikationsdatum
15.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 5/2016
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3280-7

Weitere Artikel der Ausgabe 5/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 5/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.